Cochrane · systematic review · CD012217
Wendan decoction (Traditional Chinese medicine) for schizophrenia
Deng, H, Xu, J · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 16 · 57.1%Very low 0 · 0%Low 6 · 21.4%Moderate 6 · 21.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
WENDAN DECOCTION versus PLACEBO OR NO TREATMENT for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | RR 0.53 [0.39, 0.73] | 1 study · 72 participants | Low Downgraded: risk of bias |
Mental state: Clinically important change, as defined by each study (short term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: Clinically important decline, as defined by each study (short term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse effects: Metabolic ‐ weight change (medium term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | no estimate extracted | 0 studies · 0 participants | Ungraded |
Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic outcomes: Costs due to treatment, as defined by each study (long term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | no estimate extracted | 0 studies · 0 participants | Ungraded |
Use of Western medicine: Reduced dose of Western medicine (short term) WENDAN DECOCTION vs PLACEBO OR NO TREATMENT | no estimate extracted | 0 studies · 0 participants | Ungraded |
WENDAN DECOCTION versus ANTIPSYCHOTIC DRUG for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | RR 1.18 [0.98, 1.43] | 2 studies · 140 participants | Moderate Downgraded: risk of bias |
Mental state: Average total endpoint PANSS score (short term)* WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | no estimate extracted | 2 studies · 140 participants | Low Downgraded: risk of bias |
Adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms (TESS, short term)** WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | RR 0.02 [0, 0.15] | 2 studies · 140 participants | Moderate Downgraded: risk of bias |
Adverse effects: Metabolic ‐ weight change (medium term) WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | no estimate extracted | 0 studies · 0 participants | Ungraded |
Quality of life/satisfaction with care: Clinically important in quality of life/satisfaction, as defined by each study (medium term) WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic outcomes: Costs due to treatment, as defined by each study (long term) WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | no estimate extracted | 0 studies · 0 participants | Ungraded |
Use of Western medicine: Reduced dose of Western medicine (short term) WENDAN DECOCTION vs ANTIPSYCHOTIC DRUG | no estimate extracted | 0 studies · 0 participants | Ungraded |
WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC versus NORMAL DOSE ANTIPSYCHOTIC for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | RR 0.6 [0.5, 0.72] | 6 studies · 684 participants | Moderate Downgraded: risk of bias |
Mental state: Average total endpoint PANSS score (short term)* WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 5 studies · 580 participants | Low Downgraded: risk of bias |
Adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms (TESS, short term)** WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | RR 0.46 [0.3, 0.7] | 2 studies · 308 participants | Moderate Downgraded: risk of bias |
Adverse effects: Metabolic ‐ weight change (medium term) WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | RR 0.5 [0.2, 1.24] | 1 study · 108 participants | Low Downgraded: risk of bias, imprecision |
Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic outcomes: costs due to treatment, as defined by each study (long term) WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 0 studies · 0 participants | Ungraded |
Use of Western medicine: Reduced dose of Western medicine (short‐term) WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 1 study · 107 participants | Low Downgraded: risk of bias, imprecision |
WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC versus NORMAL DOSE ANTIPSYCHOTIC for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | RR 0.69 [0.51, 0.93] | 7 studies · 522 participants | Moderate Downgraded: risk of bias |
Mental state: Average total endpoint PANSS score (short term)* WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 4 studies · 250 participants | Low Downgraded: risk of bias, indirectness |
Adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms (TESS, short term)** WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | RR 0.29 [0.16, 0.51] | 3 studies · 280 participants | Moderate Downgraded: risk of bias |
Adverse effects: Metabolic ‐ weight change (medium term) WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 0 studies · 0 participants | Ungraded |
Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 0 studies · 0 participants | Ungraded |
Economic outcomes: Costs due to treatment, as defined by each study (long term) WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 0 studies · 0 participants | Ungraded |
Use of Western medicine: Reduced dose of Western medicine (short term) WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC vs NORMAL DOSE ANTIPSYCHOTIC | no estimate extracted | 0 studies · 0 participants | Ungraded |